Removal of Mixtard30 will be costly and disrupt patient care
Danish drug company Novo Nordisk is to withdraw Mixtard30, a form of insulin used by 90,000 patients in the UK. DTB says this will be costly; if all patients switched to Novo Nordisk’s alternative Novomix30, this would cost the NHS £9M a year.
BMJ 2010; 341: c4210